Baseline characteristics
| . | MUD (donor ≥35 y) . | Haploidentical (donor <35 y) . | P . |
|---|---|---|---|
| n = 232 . | n = 187 . | ||
| Patient age, median (IQR), y | 42.7 (31.3-56.7) | 41.4 (29.2-55) | .29 |
| Donor age, median (IQR), y | 42.4 (38.4-46.3) | 25.5 (21.3-30) | <.001 |
| Patient age, n (%), y | .69 | ||
| <40 | 106 (46) | 89 (48) | |
| ≥40 | 126 (54) | 98 (52) | |
| Sex, n (%) | .59 | ||
| Male | 135 (58) | 104 (56) | |
| Female | 97 (42) | 83 (44) | |
| Sex mismatch, n (%) | .05 | ||
| Female-to-male | 36 (16) | 43 (23) | |
| Others | 195 (84) | 144 (77) | |
| Race/ethnicity, n (%) | <.001 | ||
| White, non-Hispanic | 20 (9) | 54 (29) | |
| White, Hispanic | 159 (69) | 64 (34) | |
| Black | 13 (6) | 31 (17) | |
| Asian | 15 (6) | 14 (7) | |
| Other/not specified | 25 (11) | 24 (13) | |
| Remission status, n (%) | .31 | ||
| CR1-MRD–negative | 98 (42) | 68 (36) | |
| CR1-MRD–positive | 75 (32) | 57 (30) | |
| CR1-MRD missing | 6 (3) | 3 (2) | |
| CR2 | 47 (20) | 50 (27) | |
| ≥CR3 | 6 (3) | 9 (5) | |
| Immunophenotype, n (%) | <.001 | ||
| B cell | 178 (77) | 166 (89) | |
| T cell | 33 (14) | 5 (3) | |
| Unspecified | 21 (9) | 16 (9) | |
| Philadelphia chromosome–positive/BCR-ABL1 status∗ , n (%) | .38 | ||
| No | 86 (48) | 88 (53) | |
| Yes | 92 (52) | 78 (47) | |
| Cytogenetics, n (%) | .44 | ||
| Normal | 49 (21) | 39 (21) | |
| Poor | 119 (51) | 115 (61) | |
| Missing | 64 (28) | 33 (18) | |
| Conditioning, n (%) | <.001 | ||
| MAC-TBI | 140 (60) | 74 (40) | |
| MAC chemotherapy | 38 (16) | 29 (16) | |
| Reduced-intensity conditioning/nonmyeloablative | 54 (23) | 84 (45) | |
| Graft, n (%) | <.001 | ||
| Bone marrow | 37 (16) | 79 (42) | |
| Peripheral blood | 195 (84) | 108 (58) | |
| Cytomegalovirus donor/recipient, n (%) | .02 | ||
| Positive/positive | 78 (34) | 88 (47) | |
| Positive/negative | 34 (15) | 14 (7) | |
| Negative/positive | 64 (28) | 46 (25) | |
| Negative/negative | 54 (23) | 39 (21) | |
| Karnofsky performance scale, n (%) | .49 | ||
| <90 | 93 (41) | 68 (36) | |
| ≥90 | 138 (59) | 116 (62) | |
| HCT-specific Comorbidity Index, n (%) | .05 | ||
| 0-2 | 112 (48) | 108 (58) | |
| ≥3 | 120 (52) | 79 (42) | |
| GVHD prophylaxis, n (%) | <.001 | ||
| PTCy + CNI ± mycophenolate mofetil | 0 | 187 (100) | |
| CNI + methotrexate ± others | 26 (11) | 0 | |
| CNI + mycophenolate mofetil ± others | 170 (73) | 0 | |
| CNI ± others | 36 (16) | 0 | |
| Time from diagnosis to HCT, n (%) | .02 | ||
| 0-5 mo | 98 (42) | 68 (36) | |
| 6-11 mo | 86 (37) | 58 (31) | |
| ≥12 mo | 48 (21) | 51 (33) | |
| Y of transplant, median (IQR) | 2015 (2014-2016) | 2016 (2015-2017) | <.001 |
| Follow-up among survivors, median (IQR), mo | 36.3 (24.2-49.4) | 31.5 (23.6-41.8) | .009 |
| . | MUD (donor ≥35 y) . | Haploidentical (donor <35 y) . | P . |
|---|---|---|---|
| n = 232 . | n = 187 . | ||
| Patient age, median (IQR), y | 42.7 (31.3-56.7) | 41.4 (29.2-55) | .29 |
| Donor age, median (IQR), y | 42.4 (38.4-46.3) | 25.5 (21.3-30) | <.001 |
| Patient age, n (%), y | .69 | ||
| <40 | 106 (46) | 89 (48) | |
| ≥40 | 126 (54) | 98 (52) | |
| Sex, n (%) | .59 | ||
| Male | 135 (58) | 104 (56) | |
| Female | 97 (42) | 83 (44) | |
| Sex mismatch, n (%) | .05 | ||
| Female-to-male | 36 (16) | 43 (23) | |
| Others | 195 (84) | 144 (77) | |
| Race/ethnicity, n (%) | <.001 | ||
| White, non-Hispanic | 20 (9) | 54 (29) | |
| White, Hispanic | 159 (69) | 64 (34) | |
| Black | 13 (6) | 31 (17) | |
| Asian | 15 (6) | 14 (7) | |
| Other/not specified | 25 (11) | 24 (13) | |
| Remission status, n (%) | .31 | ||
| CR1-MRD–negative | 98 (42) | 68 (36) | |
| CR1-MRD–positive | 75 (32) | 57 (30) | |
| CR1-MRD missing | 6 (3) | 3 (2) | |
| CR2 | 47 (20) | 50 (27) | |
| ≥CR3 | 6 (3) | 9 (5) | |
| Immunophenotype, n (%) | <.001 | ||
| B cell | 178 (77) | 166 (89) | |
| T cell | 33 (14) | 5 (3) | |
| Unspecified | 21 (9) | 16 (9) | |
| Philadelphia chromosome–positive/BCR-ABL1 status∗ , n (%) | .38 | ||
| No | 86 (48) | 88 (53) | |
| Yes | 92 (52) | 78 (47) | |
| Cytogenetics, n (%) | .44 | ||
| Normal | 49 (21) | 39 (21) | |
| Poor | 119 (51) | 115 (61) | |
| Missing | 64 (28) | 33 (18) | |
| Conditioning, n (%) | <.001 | ||
| MAC-TBI | 140 (60) | 74 (40) | |
| MAC chemotherapy | 38 (16) | 29 (16) | |
| Reduced-intensity conditioning/nonmyeloablative | 54 (23) | 84 (45) | |
| Graft, n (%) | <.001 | ||
| Bone marrow | 37 (16) | 79 (42) | |
| Peripheral blood | 195 (84) | 108 (58) | |
| Cytomegalovirus donor/recipient, n (%) | .02 | ||
| Positive/positive | 78 (34) | 88 (47) | |
| Positive/negative | 34 (15) | 14 (7) | |
| Negative/positive | 64 (28) | 46 (25) | |
| Negative/negative | 54 (23) | 39 (21) | |
| Karnofsky performance scale, n (%) | .49 | ||
| <90 | 93 (41) | 68 (36) | |
| ≥90 | 138 (59) | 116 (62) | |
| HCT-specific Comorbidity Index, n (%) | .05 | ||
| 0-2 | 112 (48) | 108 (58) | |
| ≥3 | 120 (52) | 79 (42) | |
| GVHD prophylaxis, n (%) | <.001 | ||
| PTCy + CNI ± mycophenolate mofetil | 0 | 187 (100) | |
| CNI + methotrexate ± others | 26 (11) | 0 | |
| CNI + mycophenolate mofetil ± others | 170 (73) | 0 | |
| CNI ± others | 36 (16) | 0 | |
| Time from diagnosis to HCT, n (%) | .02 | ||
| 0-5 mo | 98 (42) | 68 (36) | |
| 6-11 mo | 86 (37) | 58 (31) | |
| ≥12 mo | 48 (21) | 51 (33) | |
| Y of transplant, median (IQR) | 2015 (2014-2016) | 2016 (2015-2017) | <.001 |
| Follow-up among survivors, median (IQR), mo | 36.3 (24.2-49.4) | 31.5 (23.6-41.8) | .009 |
CNI, calcineurin inhibitor.
In patients with B-cell ALL.